Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05450900 · ClinicalTrials.gov registry record · Early Phase 1
Can Biotin Supplementation be Used to Mask hCG Abuse?
A Early Phase 1 study, sponsored by Sports Medicine Research and Testing Laboratory.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT05450900: Completed Early Phase 1 study, sponsored by Sports Medicine Research and Testing Laboratory.
NCT05450900 is a Early Phase 1 study that has completed, run by Sports Medicine Research and Testing Laboratory. The registered enrollment target is 10 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05450900, a Early Phase 1 study, has completed, sponsored by Sports Medicine Research and Testing Laboratory.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This sponsor is an anti-doping laboratory tasked with testing athlete samples for prohibited substances by the World Anti-Doping Agency and other agencies. This study is intended to measure: 1. Urinary/serum hCG (human chorionic gonadotropin) and urinary biotin concentrations in both treatment groups before, during, and after hCG intervention using standard immunoassay methods 2. To monitor hCG in both treatment groups before and after diafiltration of urine samples prior to analysis 3. To compare urinary and serum detectability (detection window, sensitivity) of hCG abuse in the hCG-only group compared to the hCG + biotin group
Primary Outcome
Urinary hCG concentration will be measured on different analytical platforms (Abbott, Roche, Siemens) that are dependent or not dependent on biotin-streptavidin chemistry for hCG measurement. Urinary biotin concentration will be measured using mass spectrometric techniques. Measured hCG concentrations, especially those during and after the dosing of Ovidrel, will be assessed in combination with the biotin concentration to understand the masking effect of biotin on urinary hCG measurement as it r
Interventions
- DIETARY_SUPPLEMENT biotin
- DRUG Choriogonadotropin Alpha
- OTHER Microcellulose filler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-10-27 |
| Est. Completion | 2023-02-02 |
| Phase | Early Phase 1 |
What the finished NCT05450900 record still lists
NCT05450900 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 3 interventions - of which biotin is the first listed.
NCT05450900 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05450900 about?
NCT05450900 is a clinical study titled "Can Biotin Supplementation be Used to Mask hCG Abuse?". This sponsor is an anti-doping laboratory tasked with testing athlete samples for prohibited substances by the World Anti-Doping Agency and other agencies. This study is intended to measure: 1. Urinary/serum hCG (human chorionic gonadotropin) and urinary biotin concentrations in both treatment gro...
What is the current status of trial NCT05450900?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2022-10-27. Estimated completion is 2023-02-02.
What interventions are being tested in trial NCT05450900?
The interventions under investigation include: biotin (DIETARY_SUPPLEMENT), Choriogonadotropin Alpha (DRUG), Microcellulose filler (OTHER).
Who is sponsoring clinical trial NCT05450900?
This trial is sponsored by Sports Medicine Research and Testing Laboratory, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05450900's enrollment target sits among peer trials
10 1628th of 2000 higher than 256 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI